Liquid biopsies in non-small cell lung cancer management: what can we learn from methylation status and mutant allele frequencies?
作者信息
Castellano Gina M, Pine Sharon R
机构信息
Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA.
Rutgers Graduate Program in Cellular and Molecular Pharmacology, Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA.
出版信息
Transl Lung Cancer Res. 2020 Aug;9(4):951-955. doi: 10.21037/tlcr.2020.04.05.
Abstract
摘要
相似文献
1
Liquid biopsies in non-small cell lung cancer management: what can we learn from methylation status and mutant allele frequencies?非小细胞肺癌治疗中的液体活检：我们能从甲基化状态和突变等位基因频率中学到什么？
Transl Lung Cancer Res. 2020 Aug;9(4):951-955. doi: 10.21037/tlcr.2020.04.05.
2
Early detection of the major male cancer types in blood-based liquid biopsies using a DNA methylation panel.基于 DNA 甲基化panel 的血液液体活检对主要男性癌症类型的早期检测。
Clin Epigenetics. 2019 Dec 2;11(1):175. doi: 10.1186/s13148-019-0779-x.
3
DNA methylation biomarkers discovered detect cancer in liquid biopsies from non-small cell lung cancer patients.发现的 DNA 甲基化生物标志物可检测非小细胞肺癌患者液体活检中的癌症。
Epigenetics. 2020 Apr;15(4):419-430. doi: 10.1080/15592294.2019.1695333. Epub 2019 Nov 27.
4
The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring.液体活检在非小细胞肺癌中的现状与未来：联合四种生物源进行诊断、预后、预测和疾病监测。
Curr Oncol Rep. 2018 Jul 20;20(9):70. doi: 10.1007/s11912-018-0720-z.
5
Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers.非小细胞肺癌中表皮生长因子受体（EGFR）基因的多态性、突变及扩增
PLoS Med. 2007 Apr;4(4):e125. doi: 10.1371/journal.pmed.0040125.
6
[Liquid biopsy in human non-small-cell lung cancer : Blood-based analysis of ctDNA methylation].[人类非小细胞肺癌的液体活检：基于血液的ctDNA甲基化分析]
Pathologe. 2018 Dec;39(Suppl 2):193-198. doi: 10.1007/s00292-018-0536-5.
7
Methylation analysis for multiple gene promoters in non-small cell lung cancers in high indoor air pollution region in China.中国高室内空气污染地区非小细胞肺癌中多个基因启动子的甲基化分析
Bull Cancer. 2018 Sep;105(9):746-754. doi: 10.1016/j.bulcan.2018.05.004. Epub 2018 Aug 17.
8
9
Shallow whole-genome sequencing of plasma cell-free DNA accurately differentiates small from non-small cell lung carcinoma.血浆游离 DNA 浅层全基因组测序能准确区分小细胞肺癌和非小细胞肺癌。
Genome Med. 2020 Apr 21;12(1):35. doi: 10.1186/s13073-020-00735-4.
10
Cell-free Chromatin Immunoprecipitation (cfChIP) from blood plasma can determine gene-expression in tumors from non-small-cell lung cancer patients.从血浆中进行无细胞染色质免疫沉淀（cfChIP）可以检测非小细胞肺癌患者肿瘤中的基因表达。
Lung Cancer. 2020 Sep;147:244-251. doi: 10.1016/j.lungcan.2020.07.023. Epub 2020 Jul 23.
引用本文的文献
1
The bioinformatics analysis of RIOX2 gene in lung adenocarcinoma and squamous cell carcinoma.肺腺癌和鳞癌中 RIOX2 基因的生物信息学分析。
PLoS One. 2021 Dec 2;16(12):e0259447. doi: 10.1371/journal.pone.0259447. eCollection 2021.
本文引用的文献
1
Parallel serial assessment of somatic mutation and methylation profile from circulating tumor DNA predicts treatment response and impending disease progression in osimertinib-treated lung adenocarcinoma patients.对循环肿瘤DNA的体细胞突变和甲基化谱进行平行序列评估可预测奥希替尼治疗的肺腺癌患者的治疗反应和即将发生的疾病进展。
Transl Lung Cancer Res. 2019 Dec;8(6):1016-1028. doi: 10.21037/tlcr.2019.12.09.
2
Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer.循环肿瘤 DNA 甲基化谱可实现结直肠癌的早期诊断、预后预测和筛查。
Sci Transl Med. 2020 Jan 1;12(524). doi: 10.1126/scitranslmed.aax7533.
3
Overall Survival with Osimertinib in Untreated, -Mutated Advanced NSCLC.奥希替尼治疗未经治、-突变型晚期 NSCLC 的总生存期。
N Engl J Med. 2020 Jan 2;382(1):41-50. doi: 10.1056/NEJMoa1913662. Epub 2019 Nov 21.
4
mSEPT9 (Epi proColon) Blood Test for Colorectal Cancer Screening.用于结直肠癌筛查的mSEPT9（Epi proColon）血液检测
Am Fam Physician. 2019 Jul 1;100(1):10-11.
5
A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib.肺腺癌中一种新型获得性外显子 20 EGFR M766Q 突变介导奥希替尼耐药，但对奈拉替尼和波齐替尼敏感。
J Thorac Oncol. 2019 Nov;14(11):1982-1988. doi: 10.1016/j.jtho.2019.06.015. Epub 2019 Jun 27.
6
Circulating free tumor-derived DNA to detect mutations in patients with advanced NSCLC: French subset analysis of the ASSESS study.循环游离肿瘤来源DNA检测晚期非小细胞肺癌患者的突变：ASSESS研究的法国亚组分析
J Thorac Dis. 2019 Apr;11(4):1370-1378. doi: 10.21037/jtd.2019.03.95.
7
Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer.循环肿瘤DNA检测在非转移性结直肠癌术后监测中的预后潜力
JAMA Oncol. 2019 Aug 1;5(8):1118-1123. doi: 10.1001/jamaoncol.2019.0512.
8
Towards precision medicine: advances in 5-hydroxymethylcytosine cancer biomarker discovery in liquid biopsy.迈向精准医学：液体活检中 5-羟甲基胞嘧啶癌症生物标志物发现的进展。
Cancer Commun (Lond). 2019 Mar 29;39(1):12. doi: 10.1186/s40880-019-0356-x.
9
Liquid biopsy and minimal residual disease - latest advances and implications for cure.液体活检与微小残留病灶——最新进展及其对治愈的影响。
Nat Rev Clin Oncol. 2019 Jul;16(7):409-424. doi: 10.1038/s41571-019-0187-3.
10
Detection of Minimal Residual Disease Using ctDNA in Lung Cancer: Current Evidence and Future Directions.使用 ctDNA 检测肺癌中的微小残留病灶：当前证据与未来方向。
J Thorac Oncol. 2019 Jan;14(1):16-24. doi: 10.1016/j.jtho.2018.09.022. Epub 2018 Oct 6.
Zotero 插件